Advertisement

Excellent survival regardless of disease stage in patients with advanced nasopharyngeal cancer

Abstract

Background

We present our experience in assessing the feasibility and efficacy outcomes of intensified intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) delivered to patients with nasopharyngeal carcinoma (NPC).

Methods

Between March 2009 and December 2014, 35 patients affected by advanced NPC with a median age of 53 years (range 11-77) were treated with definitive radiotherapy. Radiotherapy was delivered by helical tomotherapy with the SIB technique. The prescribed doses were 66 Gy to macroscopic disease, 60 Gy to high-risk subclinical disease, and 54 Gy to low-risk disease in 30 fractions. The daily SIB dose was 2.2 Gy to macroscopic disease.

Results

At the end of treatment 33 (94%) patients had obtained complete clearance of disease and 2 patients had died (1 of persistent disease after 3 months and 1 of cancer-unrelated causes after 4 months). At a median follow-up of 40 months (range 5-69), locoregional control rates at 2 and 4 years were 92.9% and 88.2%, respectively, and the overall survival after 4 years was 93.9%. The most significant acute toxicities were grade 2 and 3 mucositis (43%). No grade 3 and 4 late toxicities were observed; grade 2 xerostomia after 6 months from the end of treatment was reported in 11 patients; xerostomia toxicity decreased to grade 1 in 6/11 patients within 12 months.

Conclusions

These results show that intensified IMRT with SIB is an excellent strategy offering high local control rates for NPC patients with mild acute and late toxicity.

Tumori 2016; 102(4): 381 - 386

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000483

Authors

Liliana Belgioia, Almalina Bacigalupo, Stefania Vecchio, Michela Marcenaro, Francesco Pupillo, Stefano Agostinelli, Renzo Corvò

Article History

Disclosures

Financial support: None.
Conflict of interest: The authors have no actual or potential conflicts of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Division of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, Genoa - Italy
  • Division of Medical Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, Genoa - Italy
  • Division of Medical Physics, AOU IRCCS San Martino - IST National Cancer Research Institute and University, Genoa - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.